AROAPOC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase III for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According to GlobalData, Phase III drugs for Familial Chylomicronemia (Type I Hyperlipoproteinemia) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AROAPOC-3 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AROAPOC-3 overview
AROAPOC-3 is under development for the treatment of hypertriglyceridemia, mixed dyslipidemia and familial Chylomicronemia. It is administered through the subcutaneous route. The therapeutic candidate is a siRNA which acts by targeting apolipoprotein C III. It is being developed based on targeted RNAi molecule (TRiM) platform. It is a double-stranded oligomer ARO-APOC3 RNA interference-based liver targeted therapeutic.
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals (Arrowhead), formerly Arrowhead Research, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
For a complete picture of AROAPOC-3’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - AROAPOC-3 in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Premium Insights
The gold standard of business intelligence.
